Stock listing
NASDAQ:LYEL Lyell Immunopharma, Inc. Stock
Home listing (NASDAQ) of Lyell Immunopharma, Inc.
Follow Lyell Immunopharma, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:LYEL
$13.80 USD -0.09 (-0.6%)
Close on Nov 20, 2026
- Day range
- $13.30 – $14.30 USDNov 20, 2026
- Volume
- 171,085 sharesNov 20, 2026
- Market cap
- $339.3M USDAt the close on Nov 20, 2026 · price × 24.59M shares outstanding
- 52-week range
- $7.20 – $45.00 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $2.13M USDMedian day 130,954 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:LYEL · Home | $13.80 USD | -0.09 (-0.6%) | 171,085 | $13.36 | $14.30 | $13.30 | $13.89 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:LYEL · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $13.80 | -0.09 | -0.6% | $13.36 | $14.30 | $13.30 | 171,085 | |
| $13.89 | +0.22 | +1.6% | $14.05 | $14.49 | $13.50 | 114,134 | |
| $13.67 | -0.98 | -6.7% | $14.58 | $14.75 | $13.28 | 175,807 | |
| $14.65 | +0.35 | +2.4% | $14.29 | $14.93 | $13.91 | 345,037 | |
| $14.30 | -1.34 | -8.6% | $15.65 | $15.75 | $14.20 | 236,617 | |
| $15.64 | -1.22 | -7.2% | $16.70 | $16.86 | $15.50 | 130,954 | |
| $16.86 | +0.11 | +0.7% | $16.68 | $17.60 | $16.28 | 153,668 | |
| $16.75 | +1.33 | +8.6% | $15.17 | $17.01 | $14.92 | 228,147 | |
| $15.42 | +0.56 | +3.8% | $14.91 | $17.12 | $14.76 | 409,843 | |
| $14.86 | -0.14 | -0.9% | $15.75 | $16.08 | $14.75 | 250,690 | |
| $15.00 | -0.43 | -2.8% | $15.05 | $16.20 | $13.69 | 658,413 | |
| $15.43 | +4.66 | +43.3% | $12.09 | $16.73 | $12.09 | 1,101,234 | |
| $10.77 | -0.11 | -1.0% | $10.92 | $11.63 | $10.58 | 78,055 | |
| $10.88 | -0.16 | -1.4% | $11.04 | $11.40 | $10.56 | 104,063 | |
| $11.04 | -0.265 | -2.3% | $11.26 | $11.43 | $10.79 | 113,300 | |
| $11.31 | +0.375 | +3.4% | $11.00 | $11.62 | $11.00 | 149,200 | |
| $10.93 | +0.81 | +8.0% | $10.01 | $11.03 | $9.84 | 156,800 | |
| $10.12 | +0.81 | +8.7% | $9.34 | $10.14 | $9.26 | 127,900 | |
| $9.31 | -0.08 | -0.9% | $9.35 | $9.42 | $9.075 | 85,200 | |
| $9.39 | +0.01 | +0.1% | $9.33 | $9.445 | $9.05 | 101,600 | |
| $9.38 | -0.03 | -0.3% | $9.40 | $9.69 | $9.27 | 93,200 | |
| $9.41 | -0.29 | -3.0% | $9.65 | $10.12 | $9.29 | 118,300 | |
| $9.70 | +0.90 | +10.2% | $8.74 | $10.01 | $8.565 | 158,600 | |
| $8.80 | +0.68 | +8.4% | $8.00 | $9.05 | $7.92 | 212,900 | |
| $8.12 | -0.07 | -0.9% | $8.24 | $8.44 | $7.921 | 195,000 | |
| $8.19 | +0.20 | +2.5% | $8.00 | $8.44 | $7.76 | 325,000 | |
| $7.99 | +0.48 | +6.4% | $7.42 | $8.285 | $7.195 | 402,200 | |
| $7.51 | -0.76 | -9.2% | $8.27 | $8.27 | $7.39 | 187,200 | |
| $8.27 | -0.44 | -5.1% | $8.63 | $8.69 | $8.23 | 100,400 | |
| $8.71 | -0.08 | -0.9% | $8.72 | $9.10 | $8.615 | 106,800 | |
| $8.79 | +0.23 | +2.7% | $8.49 | $8.845 | $8.21 | 194,700 | |
| $8.56 | -0.05 | -0.6% | $8.48 | $8.95 | $8.38 | 184,700 | |
| $8.61 | -0.46 | -5.1% | $9.13 | $9.13 | $8.585 | 125,000 | |
| $9.07 | -0.19 | -2.1% | $9.27 | $9.31 | $8.66 | 129,400 | |
| $9.26 | -0.15 | -1.6% | $9.55 | $9.56 | $9.21 | 111,400 | |
| $9.41 | -0.38 | -3.9% | $9.80 | $9.97 | $9.36 | 115,200 | |
| $9.79 | +0.16 | +1.7% | $9.61 | $10.00 | $9.425 | 153,900 | |
| $9.63 | -0.11 | -1.1% | $9.74 | $9.74 | $9.445 | 140,800 | |
| $9.74 | -0.11 | -1.1% | $9.80 | $9.96 | $9.60 | 129,000 | |
| $9.85 | -0.27 | -2.7% | $10.16 | $10.16 | $9.81 | 108,900 | |
| $10.12 | -0.41 | -3.9% | $10.41 | $10.76 | $10.06 | 164,500 | |
| $10.53 | -0.62 | -5.6% | $11.05 | $11.05 | $10.32 | 161,500 | |
| $11.15 | +0.22 | +2.0% | $11.09 | $11.23 | $10.95 | 211,500 | |
| $10.93 | -0.08 | -0.7% | $11.02 | $11.18 | $10.60 | 142,600 | |
| $11.01 | +0.21 | +1.9% | $10.75 | $11.05 | $10.53 | 401,100 | |
| $10.80 | +0.025 | +0.2% | $11.01 | $11.06 | $10.60 | 133,000 | |
| $10.78 | -0.135 | -1.2% | $10.90 | $10.98 | $10.46 | 154,700 | |
| $10.91 | -0.42 | -3.7% | $11.29 | $11.29 | $10.55 | 184,100 | |
| $11.33 | -0.63 | -5.3% | $11.97 | $12.39 | $11.24 | 104,400 | |
| $11.96 | -0.24 | -2.0% | $12.41 | $13.00 | $11.70 | 152,200 | |
| $12.20 | -0.68 | -5.3% | $12.70 | $12.71 | $12.04 | 110,900 | |
| $12.88 | -0.65 | -4.8% | $13.52 | $13.82 | $12.71 | 101,600 | |
| $13.53 | -0.84 | -5.8% | $14.12 | $14.13 | $13.37 | 82,500 | |
| $14.37 | +0.05 | +0.3% | $14.29 | $14.68 | $13.92 | 54,100 | |
| $14.32 | -0.635 | -4.2% | $15.11 | $15.14 | $14.19 | 79,100 | |
| $14.96 | +0.43 | +3.0% | $14.49 | $14.97 | $14.25 | 56,900 | |
| $14.53 | +0.205 | +1.4% | $14.14 | $14.84 | $14.00 | 67,000 | |
| $14.32 | -0.21 | -1.4% | $14.51 | $14.71 | $14.14 | 62,800 | |
| $14.53 | -0.08 | -0.5% | $14.56 | $14.78 | $14.06 | 78,100 | |
| $14.61 | -0.19 | -1.3% | $14.67 | $15.02 | $14.33 | 88,400 | |
| $14.80 | -0.69 | -4.5% | $15.34 | $15.41 | $14.61 | 87,800 | |
| $15.49 | +0.75 | +5.1% | $15.02 | $15.68 | $14.92 | 103,000 | |
| $14.74 | -0.79 | -5.1% | $15.30 | $15.49 | $14.46 | 73,200 | |
| $15.53 | +0.18 | +1.2% | $15.54 | $16.16 | $15.20 | 104,900 | |
| $15.35 | -0.41 | -2.6% | $15.59 | $16.02 | $14.53 | 207,600 |
Splits
1 split · NASDAQ:LYEL · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-20 | Consolidation |
- Ticker
- NASDAQ:LYEL
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 4, 2026
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 51 slides
Latest news
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026
Nov 4, 2026
Closed $15.00 (-2.8%) on Nov 5, 2026
Lyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA Submission
Nov 4, 2026
Closed $15.43 (+43.3%) on Nov 4, 2026
Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory Large B-Cell Lymphoma
Nov 4, 2026
Closed $15.43 (+43.3%) on Nov 4, 2026
Lyell Immunopharma To Participate in November Investor Events
Nov 2, 2026
Closed $10.88 (-1.4%) on Nov 2, 2026
Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference
Sep 14, 2026
Closed $11.33 (-5.3%) on Sep 14, 2026
Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer
Sep 10, 2026
Closed $11.96 (-2.0%) on Sep 11, 2026
Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)
Aug 6, 2026
Closed $14.71 (+3.5%) on Aug 7, 2026
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026
Aug 6, 2026
Closed $14.71 (+3.5%) on Aug 7, 2026
Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Jun 25, 2026
Closed $12.49 (-3.9%) on Jun 25, 2026
Lyell Immunopharma, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 21 in the last 12 months · 92 in all · newest Nov 4, 2026 · oldest 2021
- Decks
- 6 decks · latest September 2026
Where Lyell Immunopharma, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:LYEL · Home listing · This page | NASDAQ | United States | USD |
| BOATS:LYEL | BOATS | United States | USD |
Valuation
EV/sales 13,099× against a median of 45.3×: 8th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $196.5M USD
- P/E
- Loss
- EV/sales
- 13,099×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.8×
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.2×
- Beta vs S&P 500
- 1.51
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Lyell Immunopharma, Inc. · NASDAQ:LYEL | US$339.3M | US$196.5M | n/a | 13,099× | n/a | 1.8× | n/a | 0.2× | 1.51 |
| AbClon, Inc. · KRX:174900 | US$348.2M | US$321.1M | n/a | 80.9× | n/a | 8.8× | −328.3% | 0.0× | n/a |
| Alector, Inc. · NASDAQ:ALEC | US$347.6M | US$208.9M | 8.4× | 1.2× | 4.9× | 3.0× | 23.9% | 0.0× | 1.72 |
| Gongwin Biopharm Holdings Co., Ltd. · TPEX:6617 | US$347.3M | US$296.6M | n/a | 232× | n/a | 4.9× | −389.6% | 0.0× | n/a |
| Onconic Therapeutics, Inc. · KRX:476060 | US$346.5M | US$299.7M | 19.1× | 4.9× | n/a | 5.4× | 29.5% | 0.0× | n/a |
| Avacta Group PLC · LSE:AVCT | US$337.8M | US$337.2M | n/a | 2,281× | n/a | 68.5× | n/a | 5.3× | n/a |
| Inovio Pharmaceuticals, Inc. · NASDAQ:INO | US$329.7M | US$7.56B | n/a | 25,303× | 3.4× | n/a | n/a | n/a | 0.70 |
| Larimar Therapeutics, Inc. · NASDAQ:LRMR | US$328.6M | US$204.7M | n/a | n/a | n/a | 3.2× | n/a | 0.1× | 1.48 |
| CytoDyn Inc. · OTC:CYDY | US$326.4M | US$345.8M | n/a | n/a | n/a | n/a | n/a | n/a | 0.44 |
| C4 Therapeutics, Inc. · NASDAQ:CCCC | US$325.7M | US$175.5M | n/a | 5.4× | n/a | 1.4× | −282.2% | 0.2× | 1.46 |
| Laekna, Inc. · HKEX:2105 | US$322.8M | US$154.7M | n/a | 9.7× | n/a | 1.8× | −214.9% | 0.0× | n/a |
| Median of the others | US$333.7M | US$298.2M | 13.8× | 45.3× | 4.1× | 4.1× | −248.6% | 0.0× | 1.46 |
Forecasts
5 strong buy · 2 buy · 1 sell · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 37.63 USD · Analysts' mean
- EPS, year to Dec 2026
- -6.69 · 1 analyst
- Revenue, year to Dec 2026
- 14.29K · 7 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Lynn Seely | President and Chief Executive Officer |
| Smital Shah | Chief Financial and Business Officer |
| Stephen Hill | Chief Operating Officer |
| Mark Meltz | General Counsel and Corporate Secretary |
| Ellen Rose | Senior Vice President, Communications and Investor Relations |
| Pablo Fenton | Associate Director, Investor Relations and Corporate Communications |
| Pablo FentonAssociate | Director, Investor Relations and Corporate |
| Bryan Selby | Senior Vice President, Clinical Development Operations |
| Peter A. Prieto | Senior Vice President, Medical Affairs |
| Ann Tomlin | Chief Human Resource Officer |
| Gary Lee | Chief Scientific Officer |
| Jarrad Aguirre | Chief Medical Officer |
| Rick Klausner | Founder & Chairman of the Board |
Board
| Director | Role |
|---|---|
| Rick Klausner | Founder & Chairman of the Board |
| Catherine Friedman | Director |
| Elizabeth Nabel | Director |
| Mark J. Bachleda | Director |
| Otis Brawley | Director |
| Sumant Ramachandra | Director |
| William Rieflin | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 4, 2026 · After close | −2.8% |
| Q2 2026 | Aug 6, 2026 · After close | +3.5% |
| Q1 2026 | May 6, 2026 · After close | −3.8% |
| Q4 2025 | Mar 13, 2026 | −14.7% |
| Q3 2025 | Nov 12, 2025 · After close | −1.3% |
| Q2 2025 | Aug 12, 2025 · After close | +2.5% |
| Q1 2025 | May 13, 2025 · After close | −3.7% |
| Q4 2024 | Mar 12, 2025 | −9.0% |
| Q3 2024 | Nov 7, 2024 · After close | 0.0% |
| Q2 2024 | Aug 7, 2024 · After close | +6.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 6, 2024 | +7.6% |
| Q4 2023 | Feb 28, 2024 · After close | +2.8% |
| Q3 2023 | Nov 7, 2023 · After close | +4.4% |
| Q2 2023 | Aug 8, 2023 · After close | −0.4% |
| Q1 2023 | May 4, 2023 · After close | +2.5% |
| Q4 2022 | Feb 28, 2023 · After close | +11.6% |
| Q3 2022 | Nov 8, 2022 · After close | −18.6% |
| Q2 2022 | Aug 4, 2022 · After close | +9.3% |
| Q1 2022 | May 10, 2022 · After close | −11.0% |
| Q4 2021 | Mar 29, 2022 · After close | +3.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 51 slides | September 2026 |
| American Society of Hematology (ASH) 2025 | Conference | 21 slides | Dec 7, 2025 |
| American Society of Hematology (ASH) 2025 | Conference | 13 slides | Dec 7, 2025 |
| International Conference on Malignant Lymphoma (ICML) 2025 | Conference | 11 slides | Jun 18, 2025 |
| Technical Presentation (June 2024) | Technical | 37 slides | Jun 26, 2024 |
| Investor Presentation (September 2023) | Investor deck | 35 slides | Sep 11, 2023 |
Financings
| Raise | Date |
|---|---|
| Private placement of private placement Update: US$80M · US$10.77 a share · Goldman Sachs +1 Dealers: Goldman Sachs, Leerink Partners Buyers: ARCH Venture Partners; Adage Capital Management LP; Caligan Partners LP; RTW Investments Use of proceeds: Extend cash runway into 2028, beyond the expected ronde-cel BLA submission and updated LYL273 clinical data | Nov 4, 2026 |
| Private placement of common stock and/or pre-funded warrants Announced: up to US$100M · US$13.32 a share Use of proceeds: Fund two pivotal-stage clinical trials of LYL314 and working capital for other general corporate purposes | Jul 25, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$17.00 a share on Jun 16, 2021.
- Price
- US$17.00 a share
- Shares offered
- 25,000,000 shares of common stock
- Offering size
- US$425 million
- Underwriters' option
- Up to 3,750,000 more shares
- Underwriters
- Goldman Sachs & Co. LLC, BofA Securities, J.P. Morgan, Morgan Stanley · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Apr 12, 2021 |
| Filed publicly | May 25, 2021 |
| Amended once | Jun 9, 2021 |
| Shares registered with an exchange | Jun 14, 2021 |
| Declared effective by the SEC | Jun 16, 2021 |
| Final prospectus, with the price | Jun 21, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jun 21, 2021 |
| EFFECT · Notice that a registration is effective | Jun 16, 2021 |
| CERT · Exchange's certificate of listing | Jun 16, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Jun 14, 2021 |
| CORRESP · Letter to the SEC | Jun 14, 2021 |
| CORRESP · Letter to the SEC | Jun 14, 2021 |
| S-1/A · Registration statement, amended | Jun 9, 2021 |
| CORRESP · Letter to the SEC | Jun 7, 2021 |
| UPLOAD · Letter from the SEC | Jun 4, 2021 |
| CORRESP · Letter to the SEC | Jun 1, 2021 |
All 17 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | May 28, 2021 |
| UPLOAD · Letter from the SEC | May 25, 2021 |
| S-1 · Registration statement | May 25, 2021 |
| DRSLTR · Letter to the SEC with a draft | May 12, 2021 |
| DRS/A · Draft registration statement, amended | May 12, 2021 |
| UPLOAD · Letter from the SEC | May 7, 2021 |
| DRS · Draft registration statement | Apr 12, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Jun 21, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 36.0K | 61.0K | 130.0K | 84.7M | 10.7M | 7.76M | 657.0K |
| Cost of revenue | 11.5M | 20.3M | 16.5M | 14.5M | 7.47M | ||
| Gross profit | -11.5M | 61.0K | 130.0K | 84.7M | 10.7M | 7.76M | 657.0K |
| Research and development | 158.7M | 171.6M | 182.9M | 159.2M | 138.7M | 182.2M | 63.6M |
| Selling, general and administrative | 45.1M | 52.0M | 67.0M | 117.3M | 89.1M | 46.9M | 39.2M |
| Operating income | -269.4M | -358.8M | -247.0M | -187.1M | -214.8M | -211.9M | -102.1M |
| Depreciation and amortization | 11.5M | 19.6M | 20.3M | 18.0M | 13.6M | 4.29M | 1.26M |
| EBITDA | -257.9M | -339.1M | -226.8M | -169.0M | -201.2M | -207.6M | -100.8M |
| Interest expense | 1.17M | 5.94M | 0 | ||||
| Income before tax | -274.4M | -343.0M | -234.6M | -183.1M | -250.2M | -204.5M | -129.4M |
| Income tax | 0 | -10.5M | -178.4M | 35.3M | -5.94M | -8.12M | |
| Net income | -274.4M | -343.0M | -234.6M | -183.1M | -250.2M | -204.5M | -129.4M |
| Earnings per share, basic | -16.06 | -26.23 | -18.70 | -0.74 | -1.84 | -15.69 | -24.04 |
| Earnings per share, diluted | -16.06 | -26.23 | -18.70 | -0.74 | -1.84 | -15.69 | -24.04 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 60.2M | 105.6M | 145.6M | 123.6M | 293.8M | 140.4M | 96.7M |
| Short-term investments | 187.0M | 264.9M | 400.6M | 516.6M | 321.0M | 472.2M | 339.4M |
| Current assets | 260.9M | 379.6M | 554.7M | 651.3M | 626.3M | 617.5M | 440.3M |
| Property, plant and equipment | 34.8M | 48.2M | 102.7M | 123.0M | 120.1M | 77.0M | 43.7M |
| Total assets | 340.1M | 490.9M | 750.0M | 937.6M | 1.13B | 908.3M | 555.6M |
| Accounts payable | 2.89M | 5.37M | 4.82M | 3.92M | 3.21M | 9.40M | 2.84M |
| Current liabilities | 49.4M | 53.8M | 34.5M | 37.0M | 46.7M | 49.3M | 22.0M |
| Total debt | 51.0M | 59.0M | 63.2M | 67.7M | 67.8M | 54.6M | 27.5M |
| Total liabilities | 91.8M | 108.0M | 95.1M | 104.3M | 197.6M | 189.8M | 147.6M |
| Shareholders' equity | 248.2M | 382.8M | 655.0M | 833.3M | 929.8M | -292.5M | -111.1M |
| Shares outstanding | 21.3M | 14.7M | 254.0M | 249.6M | 242.7M | 15.6M | 249.6M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -150.0M | -162.4M | -163.7M | -169.6M | -126.2M | -160.9M | 39.5M |
| Capital spending | -780.0K | -464.0K | -2.69M | -24.3M | -65.5M | -51.5M | -16.0M |
| Free cash flow | -150.8M | -162.9M | -166.4M | -193.8M | -191.8M | -212.4M | 23.4M |
| Cash from investing | 54.1M | 122.4M | 184.0M | -11.5M | -121.6M | -273.5M | -422.4M |
| Cash from financing | 50.4M | 1.33M | 1.74M | 10.6M | 401.2M | 476.8M | 351.2M |
| Share buybacks | 36.0M | -457.0K | 0 | 0 | -11.8M | -185.0K | |
| Change in cash | -45.5M | -38.6M | 22.1M | -170.5M | 153.4M | 42.4M | -31.8M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| S-3 · Registration statement | Nov 13, 2026 | Offer document | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 10, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 5, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2026 | Results | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 4, 2026 | Financing | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 10, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 10, 2026 | Current report | SEC |
| 4 · Change in ownership | Aug 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 25, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 27, 2026 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Jul 22, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Jul 17, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 16, 2026 | Other filings | SEC |
| S-3 · Registration statement | Jul 13, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jun 18, 2026 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 15, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 11, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 8, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 24, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 24, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 24, 2026 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 21, 2026 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Apr 15, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 13, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 8, 2026 | Other filings | SEC |
| S-3 · Registration statement | Apr 3, 2026 | Offer document | SEC |
| 4 · Change in ownership | Mar 16, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 16, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 12, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 12, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 12, 2026 | Results | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 9, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 424B5 · Prospectus | Dec 18, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Dec 16, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 11, 2025 | Other filings | SEC |
| 8-K · Current report | Dec 8, 2025 | Current report | SEC |
| S-3 · Registration statement | Dec 5, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 5, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 13, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 12, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| 3 · Initial statement of ownership | Nov 10, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 10, 2025 | Material contract | SEC |
| 8-K · Current report | Nov 3, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Oct 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 29, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 16, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Aug 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 22, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 19, 2025 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Aug 18, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2025 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Aug 13, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 13, 2025 | Other filings | SEC |
| S-3 · Registration statement | Aug 12, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 1, 2025 | Big-stake notice | SEC |
| 424B5 · Prospectus | Jul 31, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jul 31, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jul 29, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 29, 2025 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Jul 28, 2025 | Other filings | SEC |
| 8-K · Current report | Jul 25, 2025 | Material contract | SEC |
| UPLOAD · Letter from the SEC | Jul 23, 2025 | Other filings | SEC |
| S-3 · Registration statement | Jul 18, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 26, 2025 | Financing | SEC |
| 8-K · Current report | Jun 17, 2025 | Current report | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 11, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 11, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 11, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 9, 2025 | Management or board change | SEC |
| 8-K · Current report | May 28, 2025 | Current report | SEC |
| 8-K · Current report | May 21, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 21, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 21, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 10, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 8-K · Current report | Apr 1, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Mar 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 11, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 11, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 11, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 24, 2025 | Current report | SEC |
| 8-K/A · Current report, amended | Jan 10, 2025 | Current report | SEC |
| 8-K · Current report | Dec 9, 2024 | Current report | SEC |
| 424B5 · Prospectus | Dec 9, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Dec 6, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 3, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 3, 2024 | Other filings | SEC |
| S-3 · Registration statement | Nov 29, 2024 | Offer document | SEC |
| 8-K · Current report | Nov 26, 2024 | Management or board change | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 4, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 1, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 1, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Oct 31, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Oct 31, 2024 | Acquisition or disposal | SEC |
| 8-K · Current report | Oct 24, 2024 | Material contract | SEC |
| 10-Q · Quarterly report | Aug 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2024 | Results | SEC |
| 8-K · Current report | Jun 26, 2024 | Current report | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 14, 2024 | Meeting outcome | SEC |
| 424B5 · Prospectus | May 6, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | May 6, 2024 | Quarterly report | SEC |
This page holds 200 of 365 filings. Open Filings
Cap table
Built by 6ix from Lyell Immunopharma, Inc.’s releases · as of Oct 30, 2026
- Common shares
- 24,585,565
- Fully diluted
- 24,585,565
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 24,585,565 | Oct 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 30, 2026 | 24,585,565 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Heather Turner Other companies: Avalyn Pharma Inc. (Director · Since at least Apr 29, 2026); LB Pharmaceuticals Inc (Chief Executive Officer, Director · Since at least Sep 10, 2025); Terns Pharmaceuticals, Inc. (Director · Since at least Nov 18, 2024); Sangamo Therapeutics, Inc. (EVP, General Counsel & Sec. · Feb 12, 2018 – Feb 25, 2019 · Past); Atara Biotherapeutics, Inc. (Former EVP, GC & Sec. · Feb 6, 2018 – Feb 9, 2018 · Past) | Chief General Counsel · Jun 16, 2021 – Mar 16, 2022 · Past |
| Charles Newton Other companies: Keros Therapeutics, Inc. (Director · Since at least Feb 26, 2026); Novavax, Inc. (Director · Since at least Apr 25, 2025); Coherus Oncology, Inc. (Director · Since at least May 4, 2022); 2Seventy Bio Inc (Director · Mar 20, 2024 – May 13, 2025 · Past) | Chief Financial Officer · Since at least Jun 16, 2021 |
| Hans Bishop Other companies: Sana Biotechnology, Inc. (Chairman · Since at least Feb 3, 2021); Celgene Corporation (Director · Apr 18, 2018 – Nov 20, 2019 · Past); Agilent Technologies, Inc. (Director · Jul 18, 2017 – Mar 15, 2024 · Past); Juno Therapeutics Inc (CEO & President, Director · Jun 9, 2016 – Mar 5, 2018 · Past) | Director · Jun 16, 2021 – Jun 14, 2024 · Past |
| Otis W. Brawley Other companies: Agilent Technologies, Inc. (Director · Since at least Nov 17, 2021); Incyte Corporation (Director · Since at least Sep 27, 2021); PDS Biotechnology Corporation (Director · Since at least Nov 3, 2020); Theragenics Corp (Director · May 9, 2006 – May 18, 2007 · Past) | Director · Since at least Jun 16, 2021 |
| Cathy Friedman Other companies: Revolution Healthcare Acquisition Corp (Director · Mar 17, 2021 – Mar 17, 2021 · Past); Seer, Inc. (Director · Dec 3, 2020 – Jun 14, 2023 · Past); Radius Health, Inc. (Director · Feb 20, 2020 – Aug 15, 2022 · Past) | Director · Since at least Jun 16, 2021 |
| Elizabeth Nabel Other companies: Moderna, Inc. (Director · Since at least Dec 7, 2018); Medtronic plc. (Director · Since at least Sep 16, 2014); Accolade, Inc. (Director · Jun 2, 2021 – Apr 8, 2025 · Past) | Director · Since at least Jun 16, 2021 |
| Lynn Seely Other companies: AbCellera Biologics Inc. (Director · Since at least Jun 30, 2026); Blueprint Medicines Corp (Director · Since at least Jun 19, 2019); Myovant Sciences Ltd (Principal Executive Officer, Director · Apr 5, 2019 – Apr 3, 2020 · Past) | President and CEO, Director · Since at least Jun 16, 2021 |
| Matthew Lang Other companies: Structure Therapeutics, Inc. (COO & GC · Since at least Apr 15, 2026); Metsera, Inc. (CHIEF LEGAL OFFICER · Since at least Apr 28, 2025); Myovant Sciences Ltd (General Counsel & Corp. Secy. · Apr 5, 2019 – Mar 10, 2023 · Past) | Chief Business Officer · Jul 1, 2023 – Feb 10, 2025 · Past |
| William Rieflin Other companies: RAPT Therapeutics Inc (Director · Oct 30, 2019 – May 22, 2024 · Past); NGM Biopharmaceuticals Inc (Director · Apr 3, 2019 – Apr 5, 2024 · Past); XenoPort Inc (Director · May 17, 2016 – Jul 5, 2016 · Past) | Director · Since at least Jun 16, 2021 |
| Mark Meltz Other companies: Kinnate Biopharma Inc (COO GENERAL COUNSEL SECRETARY · Dec 2, 2020 – Apr 3, 2024 · Past); Audentes Therapeutics Inc (SVP, General Counsel · Mar 28, 2019 – Jan 15, 2020 · Past) | General Counsel and Corporate Secretary · Since at least Jun 9, 2025 |
All 28 people
| Person | Seat |
|---|---|
| David Shook Other companies: Nkarta, Inc. (See Remarks · Jan 1, 2023 – Jan 15, 2025 · Past) | Chief Medical Officer · Since at least Jun 9, 2025 |
| Ellen Rose Other companies: LB Pharmaceuticals Inc (Senior Vice President, Corporate Affairs · Since at least Oct 15, 2026) | Senior Vice President, Communications and Investor Relations · Since at least Dec 7, 2025 |
| Mark J. Bachleda Other companies: Galera Therapeutics, Inc. (Chief Commercial Officer · Oct 8, 2021 – Mar 16, 2023 · Past) | Director · Since at least Jun 9, 2025 |
| Richard Klausner Other companies: Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026) | Director · Since at least Jun 8, 2021 |
| Rick Klausner Other companies: Parabilis Medicines, Inc. (Founder and Chief Scientist Altos Labs, Inc. · Since at least Nov 4, 2026) | Founder & Chairman of the Board · Since at least Jun 9, 2025 |
| Ann Tomlin | Chief Human Resource Officer · Since at least Nov 5, 2026 |
| Bryan Selby | Senior Vice President, Clinical Development Operations · Since at least Nov 5, 2026 |
| Catherine Friedman | Director · Since at least Nov 5, 2026 |
| Elizabeth Homans | Chief Executive Officer, Director · Jun 16, 2021 – Mar 16, 2022 · Past |
| Gary Lee | Chief Scientific Officer · Since at least Nov 16, 2023 |
| Jarrad Aguirre | Chief Medical Officer · Since at least Jun 9, 2025 |
| Pablo Fenton | Associate Director, Investor Relations and Corporate Communications · Since at least Aug 6, 2026 |
| Pablo FentonAssociate | Director, Investor Relations and Corporate · Since at least Jun 4, 2026 |
| Peter A. Prieto | Senior Vice President, Medical Affairs · Since at least Nov 5, 2026 |
| Smital Shah | Chief Financial and Business Officer · Since at least Mar 12, 2026 |
| Stephen Hill | Chief Operating Officer · Since at least Jun 16, 2021 |
| Sumant Ramachandra | Director · Since at least Oct 31, 2024 |
| Veronica Sanchez Bulis | VP, Corporate Controller · Since at least Oct 31, 2025 |
Log in to ask 6ix AI your own questions about Lyell Immunopharma, Inc.